Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma

Cancer Biology and Therapy

Volumn 17, Issue 3, 2016, Pages 237-245

  Kim, Eun Young ^a   Cho, Eun Na ^a   Park, Heae Surng ^a   Hong, Ji Young ^b   Lim, Seri ^b,c   Youn, Jong Pil ^c   Hwang, Seung Yong ^b,c   Chang, Yoon Soo ^a,d  

^a Yonsei University College of Medicine   (South Korea)

^b Hanyang University   (South Korea)

^c Bio Core Co   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

co mutation; Compound EGFR mutation; EGFR; lung adenocarcinoma; NGS; repeated deep sequencing; simple EGFR mutation

Indexed keywords

CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; EGFR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG TARGETING; EXON; FEMALE; FOLLOW UP; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; INTRON; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; SUBSTITUTION LINE; TREATMENT OUTCOME; TUMOR GENE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION, MISSENSE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84959056463     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1139235     Document Type: Article

References (30)

1. K.W.Jung, Y.J.Won, H.J.Kong, C.M.Oh, D.H.Lee, J.S.Lee. Prediction of cancer incidence and mortality in Korea, 2014. Cancer Res Treat 2014; 46:124-30; PMID:24851103; http://dx.doi.org/10.4143/crt.2014.46.2.124
2. M.G.Kris, B.E.Johnson, L.D.Berry, D.J.Kwiatkowski, A.J.Iafrate, I.I.Wistuba,, M.Varella-Garcia, W.A.Franklin, S.L.Aronson, P.F.Su, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311:1998-2006; PMID:24846037; http://dx.doi.org/10.1001/jama.2014.3741
3. S.W.Han, T.Y.Kim, P.G.Hwang, S.Jeong, J.Kim, I.S.Choi, D.Y.Oh, J.H.Kim, D.W.Kim, D.H.Chung, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23:2493-501; PMID:15710947; http://dx.doi.org/10.1200/JCO.2005.01.388
4. Y.T.Kim, T.Y.Kim, D.S.Lee, S.J.Park, J.Y.Park, S.J.Seo, H.S.Choi, H.J.Kang, S.Hahn, C.H.Kang, et al. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer (Amsterdam, Netherlands) 2008; 59:111-8.
5. Y.H.Soung, J.W.Lee, S.Y.Kim, S.H.Seo, W.S.Park, S.W.Nam, S.Y.Song, J.H.Han, C.K.Park, J.Y.Lee, et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Archiv: an international journal of pathology 2005; 446:483-8; PMID:15815931; http://dx.doi.org/10.1007/s00428-005-1254-y
6. H.S.Kim, J.S.Sung, S.J.Yang, N.J.Kwon, L.Jin, S.T.Kim, K.H.Park, S.W.Shin, H.K.Kim, J.H.Kang, et al. Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma. PloS one 2013; 8:e81975; PMID:24376508; http://dx.doi.org/10.1371/journal.pone.0081975
7. H.Shigematsu, L.Lin, T.Takahashi, M.Nomura, M.Suzuki, I.I.Wistuba,, K.M.Fong, H.Lee, S.Toyooka, N.Shimizu, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natil Cancer Instit 2005; 97:339-46; PMID:15741570; http://dx.doi.org/10.1093/jnci/dji055
8. L.V.Sequist, D.W.Bell, T.J.Lynch, D.A.Haber. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25:587-95; PMID:17290067; http://dx.doi.org/10.1200/JCO.2006.07.3585
9. M.Tokumo, S.Toyooka, K.Kiura, H.Shigematsu, K.Tomii, M.Aoe, K.Ichimura, T.Tsuda, M.Yano, K.Tsukuda, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005; 11:1167-73; PMID:15709185
10. T.Mitsudomi, Y.Yatabe. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010; 277:301-8; PMID:19922469; http://dx.doi.org/10.1111/j.1742-4658.2009.07448.x
11. T.Mitsudomi, Y.Yatabe. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007; 98:1817-24; PMID:17888036; http://dx.doi.org/10.1111/j.1349-7006.2007.00607.x
12. P.Yeh, H.Chen, J.Andrews, R.Naser, W.Pao, L.Horn. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin Cancer Res 2013; 19:1894-901; PMID:23344264; http://dx.doi.org/10.1158/1078-0432.CCR-12-1894
13. W.Pao, J.Chmielecki. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10:760-74; PMID:20966921; http://dx.doi.org/10.1038/nrc2947
14. H.Yasuda, S.Kobayashi, D.B.Costa. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012; 13:e23-31; PMID:21764376; http://dx.doi.org/10.1016/S1470-2045(11)70129-2
15. H.Yasuda, E.Park, C.H.Yun, N.J.Sng, A.R.Lucena-Araujo, W.L.Yeo, M.S.Huberman, D.W.Cohen, S.Nakayama, K.Ishioka, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Translat Med 2013; 5:216ra177; PMID:24353160; http://dx.doi.org/10.1126/scitranslmed.3007205
16. S.Kobayashi, H.M.Canepa, A.S.Bailey, S.Nakayama, N.Yamaguchi, M.A.Goldstein, M.S.Huberman, D.B.Costa. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thor Oncol 2013; 8:45-51; PMID:23242437; http://dx.doi.org/10.1097/JTO.0b013e3182781e35
17. J.Y.Wu, C.J.Yu, Y.C.Chang, C.H.Yang, J.Y.Shih, P.C.Yang. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011; 17:3812-21; PMID:21531810; http://dx.doi.org/10.1158/1078-0432.CCR-10-3408
18. N.C.Bae, M.H.Chae, M.H.Lee, K.M.Kim, E.B.Lee, C.H.Kim, T.I.Park, S.B.Han, S.Jheon, T.H.Jung, et al. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Gen Cytogenet 2007; 173:107-13; PMID:17321325; http://dx.doi.org/10.1016/j.cancergencyto.2006.10.007
19. C.B.Meador, C.M.Micheel, M.A.Levy, C.M.Lovly, L.Horn, J.L.Warner, D.B.Johnson, Z.Zhao, I.A.Anderson, J.A.Sosman, et al. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res 2014; 20:2264-75; PMID:24599935; http://dx.doi.org/10.1158/1078-0432.CCR-13-1591
20. K.P.Ng, A.M.Hillmer, C.T.Chuah, W.C.Juan, T.K.Ko, A.S.Teo, P.N.Ariyaratne, N.Takahashi, K.Sawada, Y.Fei, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012; 18:521-8; PMID:22426421; http://dx.doi.org/10.1038/nm.2713
21. T.Kosaka, Y.Yatabe, H.Endoh, H.Kuwano, T.Takahashi, T.Mitsudomi. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64:8919-23; PMID:15604253; http://dx.doi.org/10.1158/0008-5472.CAN-04-2818
22. L.Peng, Z.Song, S.Jiao. Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation. OncoTarget Ther 2015; 8:905-10; PMID:25960661; http://dx.doi.org/10.2147/ott.s78984
23. L.S.Z.Peng, S.Jioo. Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations. Sci Rep 2014; 4:e6104; PMID:25130612; http://dx.doi.org/10.1038/srep06104.
24. J.K.Won, B.Keam, J.Koh, H.J.Cho, Y.K.Jeon, T.M.Kim, S.H.Lee, D.S.Lee, D.W.Kim, D.H.Chung. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Annal Oncol 2015; 26:348-54; PMID:25403583; http://dx.doi.org/10.1093/annonc/mdu530
25. L.Wang, H.Hu, Y.Pan, R.Wang, Y.Li, L.Shen, Y.Yu, H.Li, D.Cai, Y.Sun, et al. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PloS One 2014; 9:e88291; PMID:24533074; http://dx.doi.org/10.1371/journal.pone.0088291
26. G.M.Frampton, S.M.Ali, M.Rosenzweig, J.Chmielecki, X.Lu, T.M.Bauer, M.Akimov, J.A.Bufill, C.Lee, D.Jentz, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Dis 2015; 5:850-9; PMID:25971938; http://dx.doi.org/10.1158/2159-8290.CD-15-0285
27. P.K.Paik, A.Drilon, P.D.Fan, H.Yu, N.Rekhtman, M.S.Ginsberg, L.Borsu, N.Schultz, M.F.Berger, C.M.Rudin, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Dis 2015; 5:842-9; PMID:25971939; http://dx.doi.org/10.1158/2159-8290.CD-14-1467
28. E.M.Berge, D.L.Aisner, R.C.Doebele. Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR. J Thor Oncol 2013; 8:e83-4; PMID:23945392; http://dx.doi.org/10.1097/JTO.0b013e31829ceb8d
29. B.C.Liao, C.C.Lin, J.C.Yang. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol 2015; 27:94-101; PMID:25611025; http://dx.doi.org/10.1097/CCO.0000000000000164
30. C.E.Steuer, F.R.Khuri, S.S.Ramalingam. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer 2015; 121:E1-6; PMID:25521095; http://dx.doi.org/10.1002/cncr.29139